NASDAQ$IRMD

IRadimed Corporation · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Reported revenue growth of nearly 39% over the fourth quarter last year, supported by record bookings that grew over 48% from the fourth quarter last year.

iRadimed Corporation announced financial results for the three months and year ended December 31, 2021. Fourth quarter revenue grew nearly 39% over the fourth quarter last year and was supported by record bookings that grew over 48% from the fourth quarter last year.

  • Fourth quarter revenue grew nearly 39% over the fourth quarter last year.
  • Record bookings grew over 48% from the fourth quarter last year.
  • Net income was $3.9 million, or $0.31 per diluted share, compared to $0.6 million, or $0.05 per diluted share for the fourth quarter 2020.
  • Non-GAAP net income was $4.2 million, or $0.33 per diluted share, for the quarter ended December 31, 2021.

Headline financials

Total Revenue

$11.9M

Previous: $8.55M+38.9%
EPS (adj)

$0.33

Previous: $0.07+371.4%
Gross Profit Margin

77.9%

Previous: 75.3%+3.5%
Capital Expenditures

$91K

Previous: $93.7K-2.9%
Free Cash Flow

$3.3M

Previous: $2.4M+37.5%
Net Income

$3.9M

Previous: $600K+550.0%
Operating Income

$3.11M

Previous: $651K+377.6%
Gross Profit

$9.25M

Previous: $6.4M+44.5%
Cash & Equivalents

$62M

Previous: $50.1M+23.8%
Total Assets

$82.9M

Previous: $71.1M+16.6%
Stock-Based Comp

$392K

Previous: $318K+23.2%

Revenue & EPS history

IRadimed · Revenue · Quarterly

$11.9M

Q4 2021+38.9%vs Q4 2020
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Forward guidance

For the full year 2022, the Company expects to report revenue of $51.4 million to $52.2 million, GAAP diluted earnings per share of $0.82 to $0.90, and non-GAAP diluted earnings per share of $0.91 to $1.01, which assumes a normalized tax rate.

Tailwinds

  • Expects to report revenue of $51.4 million to $52.2 million for the full year 2022.
  • GAAP diluted earnings per share of $0.82 to $0.90 expected for the full year 2022.
  • Non-GAAP diluted earnings per share of $0.91 to $1.01 expected for the full year 2022.
  • Expects to report revenue of $12.1 million to $12.3 million for the first quarter 2022.
  • GAAP diluted earnings per share of $0.16 to $0.18 expected for the first quarter 2022.

Headwinds

  • Guidance assumes a normalized tax rate.
  • Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax.
  • Potential disruptions in our limited supply chain for our products.
  • The Company’s ability to receive FDA 510(k) clearance for new products and product candidates.
  • Unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+2.2%

Avg return

Earnings day

+2.0%

Avg return

5 days after

+2.8%

Avg return

30 days after

59%

30 / 51 earnings

Positive

+32.1%

Q2 2019

Best reaction

-20.0%

Q1 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.5%+3.4%+8.6%
Q4 2025+9.6%+4.0%+3.5%
Q3 2025+9.4%+9.8%+21.3%
Q1 2025-2.3%-3.0%+13.7%
Q4 2024-8.4%-5.8%-13.3%
Q3 2024-8.8%-0.4%+1.9%
Q2 2024-4.9%-6.6%+0.5%
Q1 2024+6.4%+4.0%+1.1%
Q4 2023-6.9%-3.3%-5.2%
Q3 2023+3.5%-1.3%+3.5%
Q2 2023+10.7%+10.4%+9.7%
Q1 2023+8.5%+8.3%+13.0%
Q4 2022+10.1%-0.3%+3.7%
Q3 2022+5.2%+6.0%+9.4%
Q2 2022-1.4%-3.2%-17.8%
Q1 2022-17.2%-21.5%-19.4%
Q4 2021+19.8%+33.5%+24.1%
Q3 2021+6.4%+5.1%+16.8%
Q2 2021+1.0%-1.8%-2.2%
Q1 2021+5.9%+9.2%+3.9%
Q4 2020-7.2%-2.4%-7.8%
Q3 2020+3.1%+2.7%+9.0%
Q2 2020-4.2%-2.7%-7.2%
Q1 2020-7.9%-8.4%+8.1%
Q4 2019+2.4%-0.5%-10.8%
Q3 2019+5.5%+1.9%-8.2%
Q2 2019+32.1%+23.6%+7.1%
Q1 2019-20.0%-15.1%-25.3%
Q4 2018-0.4%-0.9%-12.4%
Q3 2018+1.7%+4.8%+16.1%
Q2 2018+4.6%+9.8%+17.5%
Q1 2018+13.6%+15.1%+17.0%
Q4 2017-6.3%-7.3%-13.6%
Q3 2017+12.2%+7.1%+11.0%
Q2 2017+17.3%+14.9%+18.5%
Q1 2017-3.4%-3.4%-6.2%
Q4 2016-4.0%-2.8%-2.8%
Q3 2016+2.2%+0.5%+22.7%
Q2 2016+2.8%-4.6%-1.2%
Q1 2016-5.6%
Q4 2015-17.1%
Q3 2015+11.6%
Q1 2014+0.2%
Q2 2015+18.6%
Q1 2015+2.2%
Q4 2014+7.2%
Q3 2013+4.9%
Q3 2014+4.9%
Q4 2013-2.3%
Q2 2013-2.3%
Q2 2014-0.4%
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro